CARLSBAD, Calif.--(BUSINESS WIRE)--March 29, 2006--The Immune Response Corporation (OTCBB:IMNR) announced today that it has formed a Scientific Advisory Board to provide scientific and clinical direction in its development of NeuroVax(TM), its therapeutic product candidate for the treatment of multiple sclerosis (MS).
